Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LY294002
Cat. No.:
OB0225LY-0356
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by HPLC.
Size:
Product Overview
Description:
LY294002 is a specific inhibitor of phosphatidylinositol 3-kinase (PI3K), widely used in cell signaling studies.
Synonym:
LY 294002; NSC 697286; SF 1101; 154447-36-6; 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 2-Morpholino-8-phenyl-4H-chromen-4-one; 2-Morpholin-4-yl-8-phenyl-4H-chromen-4-one
CAS No.:
154447-36-6
Compound CID:
3973
Formula:
C19H17NO3
Formula Weight:
307.34
Specification
Relative Density:
1.266 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LY294002 can be used to study processes such as cell proliferation, survival and metabolism.
Library Information
Targets:
PI3K family; Casein kinase; DNA-PK
Receptors:
p110α; p110β; p110δ
Pathways:
Metabolism; Apoptosis; DNA damage/DNA repair; PI3K/Akt/mTOR signaling; Autophagy; Stem cells
Plate Number:
AOCL-5
Plate Location:
e11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
61.46 mg/mL
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
10 mg/mL; 32.5 mM
Solubility:
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.4 mg/mL (11.06 mM)
ALogP:
3.342
HBA_Count:
3
HBD_Count:
0
Rotatable Bond:
2
